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Background and aims: Glycogen storage disease type Ia (GSD Ia) is a rare metabolic disorder, caused by deficient
activity of glucose-6-phosphatase-α. It produces fasting induced hypoglycemia and hepatomegaly, usually
manifested in the first semester of life. Besides, it is also associated with growth delay, anemia, platelet dysfunction,
osteopenia and sometimes osteoporosis. Hyperlipidemia and hyperuricemia are almost always present and
hepatocellular adenomas and renal dysfunction frequent late complications.
Methods: The authors present a report of five adult patients with GSD Ia followed in internal medicine
appointments and subspecialties.
Results: Four out of five patients were diagnosed in the first 6 months of life, while the other one was diagnosed
in adult life after the discovery of hepatocellular adenomas. In two cases genetic tests were performed, being
identified the missense mutation R83C in one, and the mutation IVS4-3C > G in the intron 4 of glucose-6-phosphatase
gene, not previously described, in the other. Growth retardation was present in 3 patients, and all of them had anemia,
increased bleeding tendency and hepatocellular adenomas; osteopenia/osteoporosis was present in three cases. All but
one patient had marked hyperlipidemia and hyperuricemia, with evidence of endothelial dysfunction in one case and
of brain damage with refractory epilepsy in another case. Proteinuria was present in two cases and end-stage renal
disease in another case. There was a great variability in the dietary measures; in one case, liver transplantation was
performed, with correction of the metabolic derangements.
Conclusions: Hyperlipidemia is almost always present and only partially responds to dietary and drug therapy; liver
transplantation is the only definitive solution. Although its association with premature atherosclerosis is rare, there have
been reports of endothelial dysfunction, raising the possibility for increased cardiovascular risk in this group of patients.
Being a rare disease, no single metabolic center has experience with large numbers of patients and the
recommendations are based on clinical experience more than large scale studies.
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Hyperlipidemia, HyperuricemiaBackground
Glycogen storage disease type I (GSD I) comprises a
group of relatively rare autosomal recessive inherited
metabolic disorders. It is caused by deficient activity of
glucose-6-phosphatase system (G6Pase), an enzyme com-
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reproduction in any medium, provided the orgluconeogenesis [1]. This complex is required for the hy-
drolysis of glucose-6-phosphate (G6P) into glucose and in-
organic phosphate [2].
The annual incidence is about 1/100000 births [1-3] and
the carrier frequency of 1 in 150 [4], being the GSD type
Ia (McKusick, #232200) the more frequent type, account-
ing for 80% of the GSD I patients. It is caused by muta-
tions in the G6PC, located on chromosome 17q21, which
encodes the catalytic subunit of glucose-6-phosphatase-α
(G6Pase-α), whose expression is limited to the liver,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions have been identified [5,6].
The disturbed glucose homeostasis associated with the
inability to breakdown glycogen stores [7] makes patients
prone to fast induced hypoglycemia, with secondary meta-
bolic derangements: hyperlactacidemia, hyperlipidemia
and hyperuricemia. Another common manifestation is a
protruded abdomen due to marked hepatomegaly; pa-
tients usually present before 1 year and have a round “doll
like” face, growth and psychomotor delay and late onset of
puberty, subclinical muscle weakness, osteopenia, platelet
dysfunction, with bleeding tendency, anemia and intermit-
tent diarrhea; in women polycystic ovaries are usually
found [8].
The diagnosis can be based on clinical and biochemical
findings, functional tests, enzyme assays of liver biopsy tis-
sue and mutation analysis; currently, the increased
knowledge of the genetic basis of GSD I makes the
mutation analysis the method of choice for confirming
the diagnosis [1,2,9].
A poor metabolic control may lead to long term compli-
cations, namely development of hepatocellular adenomas
(HCA), renal dysfunction, gout and nephrocalcinosis asso-
ciated with hyperuricemia, and increased risk of pancrea-
titis, related to severe hypertrigliceridemia [1,2].
The aim of the treatment, which is mainly dietary, is
to maintain a nearly euglycemic state to prevent second-
ary metabolic disturbances, neurologic involvement and
assure normal growth [2,9].
The rarity of this condition implies that no single
metabolic centre has experience with large number of
patients. Being the diagnosis made usually in childhood,
the follow up is done in pediatric centers. As the life ex-
pectancy has improved considerably, these patients
reach adult life and need to maintain follow up of the
complications associated with the natural history of the
disease. One of the manifestations almost always present
is severe hyperlipidemia, rarely associated with prema-
ture atherosclerosis, although some studies report an in-
creased cardiovascular risk [10]. GSD I affects many
organ systems (renal, gastrointestinal, hematological,
bone, cardiovascular, etc.) and a multidisciplinary ap-
proach, including nutritional support, is required to
ameliorate the complications frequently present. It is im-
portant to be familiarized with the disease.
The authors present the report of five adult patients
with GSD type Ia followed in internal medicine appoint-
ments and subspecialties [1,9].
Case presentation
Case 1
The first case refers to a 33 year-old man, diagnosed
with GSD type Ia at five months of age. Three days after
an uncomplicated birth from second degree relativeparents, he had a seizure related to severe hypoglycemia
(1,27 mmol/L), which recurred at four and five months.
By this time, a protruded abdomen associated with en-
larged liver was noted (13 cm bellow costal margin),
with elevated liver enzymes (six times the upper limit of
normal), lactic acidosis e hyperuricemia (523 mcmol/L,
with normal range between 118 and 356 mcmol/L).
To confirm the diagnosis two functional tests were
performed: the injection of glucagon caused an elevation
of lactate and uric acid and a decrease in serum glucose,
and the administration of galactose didn’t had any effect
on glycemia, proving the absence of G6Pase-α, which
was confirmed by liver biopsy four years later, also show-
ing increased glycogen storage in the liver. The mutation
analysis, performed at the age of 20 revealed a homozy-
gous mutation (IVS4-3C > G) in the intron 4 of the
G6PC, also present in both is parents as a heterozygous
trait. The family history of our proband was marked by
the death in the neonatal period of two older sisters, the
first with hepatomegaly and the second with seizures
and suspected congenital heart disease.
During childhood he had poor metabolic control, with
frequent episodes of hypoglycemia and acidosis, epistaxis
and muscle weakness, which improved only partially after
he was started on uncooked cornstarch (UCCS) at the age
of 4 years and continuous nocturnal gastric drip feeding
(CNGDF) at the age of 5, replaced when 10 years with
two nocturnal administrations of UCCS, maintained in
adulthood.
Because he had short stature and delayed puberty he
started testosterone supplementation at 15 years. A cog-
nitive impairment was also noted (global IQ of 67). He
has now a height of 1,51 m and a weight of 56 Kg (body
mass index of 25,6 Kg/m2).
The unsatisfactory metabolic control led to hyperuri-
cemia, under therapy with alopurinol 300 mg once daily
since he was 9, and hyperlipidemia since the age of 20,
with total cholesterol over 10 mmol/L and triglycerides
over 21 mmol/L, with raised apolipoprotein B100 and
Apolipoprotein B100/Apolipoprotein A1 ratio. He was
started on fibrates at 25, with good response (triglycer-
ides bellow 3 mmol/L), but this medication was with-
drawn after he developed myalgia and muscle weakness
related with rhabdomyolysis (creatine kinase over 29000
U/L). Despite this severe hyperlipidemia, there are no
signs of atherosclerotic lesions, with normal carotid
ultrasound and exercise ECG.
He has sustained hepatomegaly and steatosis since in-
fancy; after 20 years he developed multiple HCA, the lar-
gest over 5 cm, whose histology revealed focal nodular
hyperplasia. Until now there are no signs of malignant
transformation.
Since childhood he had frequent hospital admissions
for upper gastrointestinal bleeding, being diagnosed with
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ted to an exploratory laparotomy for the same reason,
without identification of the source of the bleeding.
Later, an esophagogastroduodenoscopy revealed a raised
formation in the duodenal bulbous, which was biopsied
and showed adenomatous changes. Recently, he had an-
other episode of upper gastrointestinal bleeding: a well
differentiated neuroendocrine tumor of the first portion
of the duodenum, with lymph node metastasis was diag-
nosed after exploratory laparotomy.
Our patient also suffers from renal dysfunction. Besides
an episode of acute glomerulonephritis without identifiable
cause at 14 years, he has proteinuria since the age of 6,
under therapy with captopril 25 mg twice daily started
when 17 years old. He has neither nephrocalcinosis nor
urolithiasis and is under therapy with citrate supplementa-
tion since childhood. Notwithstanding being under therapy,
he developed nephrotic range proteinuria (over 5 g/day)
which evolved recently to end-stage renal disease, needing
to start hemodialysis.
Furthermore he also has low bone mineral density di-
agnosed at 18 years (Tscore of −2,9 at lumbar spine and
Tscore of −3,6 at the femur neck, Z score of −3,21) and
chronic anemia since infancy, with need for frequent
supplementation with iron and/or folic acid. He had two
episodes of facial palsy, the first one at 15 years.
In the present moment he is under therapy with iron,
folic acid, calcium and vitamin D, angiotensin converting
enzyme inhibitor, angiotensin receptor blocker, alopurinol,
statin and darbopoetin.
Case 2
The second case refers to a 51 year-old man, diagnosed
with GSD type Ia in adulthood (30 years old), after the de-
tection four years earlier of hepatomegaly with multiple
adenomas, the largest with 11 cm of diameter. The diag-
nosis was confirmed by deficiency of G6Pase-α activity in
liver biopsy tissue and evidence of hyperlactacidemia.
There is no information about whether genetic tests were
performed.
Besides frequent epistaxis and an episode of enteritis,
he had a normal childhood, without symptomatic
hypoglycemic episodes (median fast glucose determina-
tions of 3,3 mmol/L) as long he maintained frequent
meals with carbohydrate rich food.
When 15 years old, short stature and delayed puberty
were noticed and he was started, at first, on human chori-
onic gonadotropin, and then testosterone supplementation.
Three years later, he was admitted with hyperuricemia
(over 700 mcmol/L) associated gouty arthritis and he was
started on alopurinol 300 mg once daily. His blood chemis-
try revealed hyperlactacidemia and hyperlipidemia with
total cholesterol over 7,7 mmol/L and triglyceride over
11,2 mmol/L. Apolipoprotein B100 and ApolipoproteinB100/Apolipoprotein A1 ratio were also elevated. He was
started on ciprofibrate 100 mg once daily at 36 years, with
poor response, replaced by fenofibrate 267 mg once daily
combined with nicotinic acid 1 g twice daily, with good re-
sponse (total cholesterol over 8 mmol/L and triglycerides
over 4,8 mmol/L). The carotid ultrasound revealed athero-
sclerotic plaques, without hemodynamically significant
stenosis and the electrocardiogram was suggestive of
antero-lateral ischemia, not confirmed on myocardial per-
fusion scan. At 47 years old, omega-3-acid ethyl ester 1 g
twice daily was introduced, in association with fenofibrate
and nicotinic acid, with better response (total cholesterol
below 5,5 mmol/L and triglycerides below 2,5 mmol/L).
Moreover, he had iron deficiency anemia known from
26 years old, refractory to iron supplementation. During
follow up low bone mineral density was noticed (Tscore
of – 3,3 at the lumbar spine and Tscore of −1,1 at the
femur neck, Z score not available), with significant gain
of bone mineral density after 3 years of therapy with
biphosphonates. Important proteinuria was also noted
(over 500 mg/24 hours), with slight elevation of creatin-
ine (116 mcmol/L), which warranted a nephrologist re-
ferral. No urolithiasis was present, although he referred
past history of renal colic. Gouty arthritis crisis occurred
monthly and high blood pressure was diagnosed, with
the need for antihypertensive therapy.
About his family history, he is the oldest of three broth-
ers (the youngest with 47 and 41 years old, respectively)
with the same diagnosis, the former with end-stage renal
disease (focal and segmental glomerulosclerosis), under
hemodialysis. In respect to offspring, he has a healthy
daughter.
Furthermore short stature (height of 1,56 m, weight of
54 Kg and body mass index of 22 Kg/m2) and hepato-
megaly, his physical exam is unremarkable. No cognitive
dysfunction is noted.
After being diagnosed, he was started on UCCS,
interrupted for bad compliance.
He is currently under therapy with losartan, acetylsali-
cylic acid, iron, folic acid, alopurinol, fenofibrate, omega-
3-acid ethyl esters, nicotinic acid plus laropiprant and
alendronic acid plus colecalciferol.
Case 3
The third case refers to a 28 year-old woman diag-
nosed with glycogen storage disease type Ia in the
neonatal period. She presented from birth with sei-
zures and severe hypoglycemia; parenteral nutrition
was instituted at first, then continuous enteric nutri-
tion for a period of time, followed by continuous en-
teric nutrition during the night, replaced by frequent
meals with maltodextrin and uncooked cornstarch as
she grew older. Enzymatic studies performed in the
liver tissue biopsy were suggestive of the disease, and
Carvalho et al. Journal of Diabetes & Metabolic Disorders 2013, 12:25 Page 4 of 10
http://www.jdmdonline.com/content/12/25a homozygous R83C mutation in the exon 2 of G6PC
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Since childhood she was frequently admitted with sei-
zures and gastrointestinal and upper airway infections.
She has hepatomegaly with multiple hepatocelullar ad-
enomas, the largest with 4 cm of diameter, first diagnosed
at 16 years old. She also has low bone mineral density
(Tscore of −1,3 at the lumbar spine and Tscore −0,69 at the
femur neck, with a Z score of – 0,6), sideropenic anemia
and polycystic ovaries.
Unlike other cases, she has hypouricemia (71 mcmol/L)
and a normal lipid profile, with total cholesterol below 5,5
mmol/L and triglycerides below 1,5 mmol/L; her HDL-
cholesterol is raised (2 mmol/L). She also has an elevated
Apolipoprotein A1, with normal Apolipoprotein B100 and
Apolipoprotein B100/Apolipoprotein A1 ratio. There are
no signs of renal involvement, namely proteinuria.
Short stature is a feature present in this patient
(height of 1,5 m, weight of 60 Kg, and body mass index
of 26, 7 Kg/m2) and during follow up there has been a
weight gain associated with accumulation of fat in the
subcutaneous tissue (lipomatosis) in connection with
an enriched carbohydrate diet and frequent adminis-
trations of UCCS to prevent hypoglycemia. As in our
first case, she has cognitive dysfunction, with a global
IQ of 71.
Furthermore, she suffers from a refractory form of epi-
lepsy, with almost daily crisis, not always related to
hypoglycemic episodes. The electroencephalogram re-
vealed interictal epileptic discharges in the right frontal
region and the magnetic resonance imaging showed sub-
cortical gliosis, right parieto-occipital atrophy, with en-
hanced sulcus and smaller right hemisphere.
She is now under therapy with levetiracetam 1000 mg
twice daily, oxcarbamazepine 600 mg three times daily,
clobazam 20 mg twice daily, sertraline 50 mg once daily,
folic acid once daily, ferrous sulfate once daily and
omeprazol once daily.
Case 4
The forth case refers to a 36 year-old woman, presenting
with vomiting, weight loss, protruding abdomen and
hypoglycemic seizure when 2 months old. She had been
previously admitted in the first week of life with
vomiting. Epistaxis was frequent.
GSD type Ia was confirmed when 3 years old by liver
biopsy (absence of G6Pase-α activity). There is no infor-
mation whether genetic tests were performed.
HCA were identified very early, when 11 years old,
and by this time she began continuous nocturnal gastric
drip feeding, replaced by frequent meals and UCCS
when 21 years-old.
Besides fasting hypoglycemia, she also had a mild hyper-
lipidemia (total cholesterol over 7,2 mmol/L; triglyceridesover 3,4 mmol/L), with low HDL-cholesterol and raised
Apolipoprotein B 100 and Apolipoprotein B100/Apolipo-
protein A1 ratio. Hyperuricemia (uric acid over 550
mcmol/L) and mild normocytic anemia were also present.
Her renal function is normal, without significant
proteinuria.
She has normal mineral bone density (Tscore of 0,6 at
the lumbar spine and Tscore of 0,1 at the femur neck, with
a Z score of 0,6 and 0,2, respectively) and irregular men-
struation cycles. She has normal stature (height of 1,62 m,
weight of 65 Kg, and body mass index of 24, 7 Kg/m2)
and a normal cognitive function, with a college degree.
When she was 27 years old, having multiple HCA, the
largest with 6 cm of diameter, she had liver transplant-
ation. The anathomopathology revealed portal fibrosis,
steatosis and multiple HCA and epithelioid granulomas.
After liver transplantation her hypoglycemic crises,
hyperlipidemia and hyperuricemia were corrected, with-
out the need for pharmacological intervention.
Later on (2 years after transplantation) she became
pregnant and delivered a healthy boy (38 weeks of gesta-
tion). During pregnancy there was a raise in liver en-
zymes and the liver biopsy revealed moderate late acute
cellular rejection of the liver graft, with the need for
corticotherapy and adjustment of the immunosuppres-
sive therapy.
During follow up depression was noted, with the need
for anti-depressant medication. She is now under
immunosuppressors.
Case 5
The fifth case refers to a 29 year-old man, sib to the pre-
vious patient, diagnosed with GSD Ia when 2 months
old, as he had hypoglycemia, hyperlactacidemia and hep-
atomegaly, in association with a suggestive family history.
His parents weren’t consanguineous. When 3 months, he
started dietary treatment with frequent meals (every 3
hours), including 2 meals in the nocturnal period. In spite
of that, he developed hyperlipidemia (total cholesterol
over 4 mmol/L, triglycerides over 7 mmol/L), hyperurice-
mia (uric acid over 500 mcmol/L) and growth failure, and
so, he started continuous nocturnal nasogastric drip feed-
ing when he was 7 years, with recovery of normal growth.
This dietary treatment was replaced with frequent meals
and UCCS when 14 years old. His hyperlipidemia and hy-
peruricemia weren’t corrected with the dietary treatment,
with the need for introduction of gemphibrozile and
alopurinol when 19.
During adolescence, he had bad dietary treatment
compliance, and he maintained marked hepatomegaly
and steatosis, being diagnoses with multiple HCA when
19, the largest with 6 cm in diameter.
Besides, he has mild normocytic anemia and occa-
sional epistaxis. He has now a height of 1,77 m, weight
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hyperlipidemia (total cholesterol over 5 mmol/L, triglycerides
over 11 mmol/L), low HDL-cholesterol and hyperuricemia.
He also developed proteinuria (400 mg/24 hours).
Table 1 resume the main findings of our five case
reports.
Discussion
In the European Study on GSD type I (ESGSD I) almost
13% of the patients with GSD Ia presented before the age
of 1 month and 50% presented between 1 and 6 months
[1]. Fast-induced hypoglycemia and hyperlactacidemia may
be the first symptoms in the neonatal period; more com-
monly, the presenting feature is a marked hepatomegaly
around 3 to 6 months, which may be present at birth in
some cases [2]. In our case series, hypoglycemic seizure in
the neonatal period was the presenting symptom in the first
and third cases, being hepatomegaly diagnosed when 5
months in the first case. Hypoglycemia and hepatomegaly
presented at 2 months in cases 4 and 5. Exceptionally, the
diagnosis was made in adulthood in one case by the pres-
ence of HCA. This patient didn’t have symptomatic
hypoglycemia during childhood, but had hyperlactacidemia,
which can be protective against cerebral symptoms of
hypoglycemia, seeing that it may be used as an alternative
fuel in cerebral metabolism [1,2,9].
The disturbed glucose homeostasis in GSD Ia can
lead to secondary metabolic derangements, mainly
hyperlactacidemia, hyperlipidemia and hyperuricemia.
Severe mixed hyperlipidemia and hepatic steatosis are
present in most cases: elevated cholesterol was reported
in 76% of cases and elevated triglycerides in 100%, in
one study [11]. The underlying mechanisms responsible
for hyperlypidemia are still largely unknown [12]. The
marked hyperlipidemia may be due to increased de novo
lipidogenesis and release of lipids into the blood com-
partment, owing to increased levels of acetyl coenzyme
A [2,8,13], and decreased clearance and uptake, in ac-
count of reduced activity of lipoprotein lipase and hep-
atic lipase; so, lipolysis of circulation lipoproteins is
impaired, leading to decreased triglyceride clearance.
Also, the diminished uptake of low density lipoproteins
(LDL) particles may contribute to the hypercholesterol-
emia often present [13]. Besides, the accumulation of
G6P in the liver tissue may play a role through the activa-
tion of transcription of lipidogenic genes [8]. Some studies
have demonstrated an increased production of very low
density lipoproteins (VLDL), especially triglyceride-rich
VLDL particles, related to the low concentration of insulin
found in GSD type I patients, as insulin is known to sup-
press hepatic VLDL production [12-14]. This way, GSD
type Ia patients have an increased number of high size
(due to the accumulation of triglycerides) VLDL and LDL
particles, associated with increased levels of ApoB100, anddecreased high density lipoprotein (HDL) cholesterol and
Apo A1 [13]. All of our male patients have marked hyper-
lipidemia, with raised Apo B100 levels. One of our female
patients had mild hyperlipidemia, corrected after liver
transplantation; opposed to most of the reports, our third
case has normal lipid values, with a raised Apo A1 and
HDL-cholesterol, which makes as suspect of presence of
another metabolic defect, which counterbalances the
hyperlipidemia frequently present in GSD Ia.
Despite marked hyperlipidemia since young ages, pre-
mature atherosclerosis [15,16] has rarely been reported,
unless associated with renal disease; protective factors
[1,12] may have a role, such as diminished platelet ag-
gregation, hyperuricemia, increased levels of apolipopro-
tein E and decreased susceptibility of LDL to oxidation.
However, a recent study involving 28 patients with GSD
type I reported arterial dysfunction, with increased ca-
rotid intima media thickness, raising the possibility of
increased cardiovascular risk in this group of patients
[10]. This manifestation of subclinical atherosclerosis is
present in our 2nd case, in which, overt renal disease is
absent.
Hyperlipidemia only partially responds to intensive
dietary treatment, consisting of frequent meals, continu-
ous nocturnal gastric drip feeding (CNGDF) or ingestion
of slow-absorption carbohydrates [uncooked cornstarch
(UCCS)] [5,8,17]. Recently, a novel dietary treatment,
medium-chain triglycerides, which are absorbed via the
portal vein without incorporation into chylomicrons, has
demonstrated beneficial effects on blood triglycerides,
lactic acid and glycemia, in a pilot study [18].
To reduce the risk of cholelithiasis and pancreatitis tri-
glycerides lowering drugs are indicated; fibrates should
be used, as they, through the activation of PPARα, in-
crease lipoprotein lipase activity and have been shown to
decrease triglyceride levels in this patients [12]; nicotinic
acid can also be used [8]. Statins, which can lower
plasma cholesterol levels, seems not to be indicated, un-
less progressive renal insufficiency occurs, since prema-
ture atherosclerosis is rare [8,12]. However, more studies
are needed to confirm or deny the presence of endothe-
lial dysfunction in GSD type I patients. In what concerns
fish oil supplements, they have been shown to improve
hyperlipidemia in these patients [19], although with a
modest effect (10 to 15% reduction of triglycerides com-
pared with 50% achieved with fibrates) in one study [14];
however, the effect obtained isn’t long lasting and fish oil
could lead to increased lipoprotein oxidation, augmenting
atherogenicity [8,15]; moreover, they reduce platelet ag-
gregation and prolong bleeding time, and may exacerbate
the bleeding tendency present in this disease [7]; so they
are not indicated. In three of our patients fibrates were in-
troduced; in one case it was associated with nicotinic acid
with reduction of triglyceride levels of more than 60%;
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lipid reduction. In other case, fibrates were withdrawn, as
they were associated with myosytis, although they were
able to reduce triglyceride levels in about 70%; this patient
has now started a statin, since he has end stage renal
disease.
Hyperuricemia, reported to be present in 89% of the
cases in one study [11], results from both increased pro-
duction (decreased intra-hepatic phosphate concentration
stimulates the degradation pathway of adenine nucleo-
tides) and decreased renal clearance (competitive inhib-
ition of uric acid excretion by lactate) [2,8]. Complications
due to hyperuricemia can occur, being urolithiasis and
gouty arthritis the most frequent [1]. Despite this risk it
might be advisable to keep uric acid concentration near
the upper limit of normal range, since it is a potent radical
scavenger [1,8], with a possible protective role in the de-
velopment of atherosclerosis. All but the third patient had
hyperuricemia, with the need for treatment with xanthine
oxidase inhibitor in 3 cases, one of them starting before
10 years old. In one case frequent gouty arthritis episodes
were present. Notwithstanding treatment, they maintain
elevated uric acid concentrations. On the other hand, the
third case, despite the presence of other complications,
has hypouricemia for unknown reason.
Several mutations have been identified through the
coding and exon-intron junction regions of G6PC; in
spite of not being more prevalent in any ethnic group,
there are mutations that are unique to Caucasian, His-
panic, Asian and Jewish populations. Two of our cases
have an identified mutation: in the third case, the
missence mutation R83C in the exon 2 of the G6PC was
found, one of the most frequent in the Caucasian popu-
lation and known to completely abolish G6Pase-α en-
zyme activity [5,6]. In the first case, the mutation found
was IVS4-3C > G in the intron 4, which, till now, hasn’t
been described in literature [3,5,6]; the functional tests
and enzyme assays performed proved absence of G6Pase
activity in this patient; analyzing all 5 cases this is prob-
ably the one with most severe disease expression. Until
now a correlation between genotype and phenotype
hasn’t been found [3,5].
Two of our patients have borderline mental develop-
ment (IQ 65–85), which is related to poor metabolic
control, with frequent hypoglycemic episodes. In fact, al-
tered brain function and structure, with abnormal elec-
troencephalograms and magnetic resonance imaging
(dilation of occipital horns and/or hyperintensity of sub-
cortical white matter in the occipital or parietal lobes),
might be associated with recurrent severe hypoglycemia
[20]. Our third case presents brain damage and suffers
from a refractory form of epilepsy, with crises not always
related to hypoglycemic episodes. The other three cases
have normal cognitive function.GSD type Ia is characterized by growth retardation
and delayed puberty, associated with poor metabolic
control, particularly chronic metabolic acidosis, which
interferes with growth hormone activity [21]; adequate
dietary therapy has the ability to improve growth [2].
There is no place for growth hormone therapy nor tes-
tosterone or oestrogen supplementation, as they are not
associated with improvement of the final height [8]. This
could, in fact, be observed in the first two cases: despite
testosterone supplementation to induce puberty, their
final height wasn’t improved and both of them are short
stature. On the other hand, in the fifth case, the intro-
duction of CNGDF was associated with recovery of nor-
mal growth and both the fourth and fifth case are
normal stature.
Besides hyperlipidemia and hepatomegaly, GSD type
Ia patients usually present with anemia and increased
bleeding tendency; anemia is reported in 81% of adult
patients [11], and normally refractory to iron therapy; it
may be associated with an up regulated production by
HCA of hepcidin; this peptide hormone controls the in-
testinal iron absorption and release of iron from macro-
phages [2,4,8]. All of our cases had anemia, some since
childhood before the presence of adenomas being detected.
Unfortunately, hepcidin serum levels weren’t measured.
Platelet dysfunction is common and recurrent epistaxis or
gastrointestinal bleeding can be troublesome [1,2,8]. Four
of our cases had frequent epistaxis; in one case recurrent
episodes of upper gastrointestinal bleeding since childhood
were associated with frequent hospital admissions and the
need for exploratory laparotomy when 18 years old; later,
adenomatous changes in the duodenal bulbous were iden-
tified as the source of bleeding; recently, a well differenti-
ated neuroendocrine tumor of the duodenal wall was
diagnosed, being at the moment under study.
Osteopenia, present in 55% of patients in a report in-
volving 42 subjects with GSD type Ia [22], can be a risk
factor for fractures later in life; it is thought to be a re-
sult of decreased bone matrix formation and decreased
mineralization [8], probably in relation with muscle
weakness, chronic acidosis and hypertriglyceridemia
[23]; additionally, the hypercalciuria associated with
hyperlactacidemia may contribute to the failure of nor-
mal bone accretion, since bone may have an important
role as a buffer for the acid loads [24]. Beyond that, a lac-
tose restricted diet may produce calcium depletion, mak-
ing reasonable the use of calcium supplements in these
patients [2,8,21,24]. In one report, an association between
low bone mineral density and low 25-hydroxy-vitamin D
concentration was found [22], putting on scope the need
for vitamin D supplementation. Since a high turnover can
contribute to osteopenia, biphosphonates known to de-
crease bone turnover, may be of value in the treatment of
osteoporosis in GSD type Ia patients [21]. Our first two
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mineral density gain after introduction of biphosphonates.
The third case has osteopenia and the other two cases
have normal bone mineral density.
The advances in dietary treatment resulted in longer
survival rates and so, complications such as HCA and
renal disease can occur.
HCA are usually detected between the 2nd and 3rd de-
cades of life, with frequencies ranging from 16% to 75%,
equal in both sexes [1,25]. The mechanism responsible
for their development remains unclear: perhaps a sub-
optimal metabolic control, with hypertriglyceridemia
and hyperlactacidemia [25,26], a hormonal imbalance
between high glucagon and low insulin, or cellular glyco-
gen overload [21] may play a role. Despite advancements
in therapy, the incidence of adenoma formation remained
largely unchanged over the past decades [25]; a reduction
in size and/or number of adenomas has been observed in
some patients under optimal metabolic control. HCA can
produce symptoms related to mechanical compression or
acute hemorrhage. Furthermore, albeit rare, malignant
transformation into hepatocellular carcinomas can occur
[1,8,27]. This implies that a regular follow up is needed:
liver ultrasound once a year for the first 10 years; after
that, once a year magnetic resonance imaging may be pro-
posed. Should hepatic lesions be detected, the follow up
must be intensified, with liver ultrasound or MRI every 3
to 6 months [2]. Serum α-fetoprotein and carcino-
embryonal antigen can be used for malignant transform-
ation screening, although false negatives can occur [8].
If recurrence of adenomas or increased risk for hepatocel-
lular carcinoma exists, liver transplantation is a valid thera-
peutic option [4,8], as long as metastatic hepatocellular
carcinoma isn’t present [9]. Liver transplantation has the
ability to correct metabolic defects, namely hypoglycemia,
hyperlipidemia, hyperuricemia and growth retardation, im-
proving the quality of life [28]. However, it doesn’t seem to
have any effect on the prevention of renal failure [8,29].
Combined liver-kidney transplantation can resolve both
problems, and should be considered in GSD Ia patients with
kidney dysfunction [30].
All of our patients have multiple, large liver adenomas;
in case one, there was some regression in size and num-
ber of adenomas during follow up; on the other hand, in
case 5 the number and size of adenomas raised despite
optimization of dietary therapy during childhood. In the
second case, the diagnosis was made during adulthood
by the presence of HCA. Its recognition in adult age, if
other manifestations can be found (in our patient
hyperlactacidemia and growth retardation were present),
should prompt the search for GSD type Ia [27]. In our
fourth patient liver adenomas were recognized in the
earliest age (11 years old), and she was transplanted
when 27 years, with complete resolution of themetabolic imbalance. Renal disease wasn’t present before
transplant and still there are no signs of renal involve-
ment. In this case, liver transplantation was complicated
by late acute cellular rejection, resolved after adjusting
immunosuppressive therapy.
One of the most serious age related complications of
GSD type Ia is renal disease, virtually present in all inef-
fectively treated patients [31]. Both glomerular and tubu-
lar functions may be affected. The first manifestation of
glomerular disease is hyperfiltration with subsequent
microalbuminuria, and then proteinuria and hyperten-
sion, which lately lead to renal failure, with a natural his-
tory similar to the renal disease in type 1 diabetes
mellitus [1,2]. The pathological findings include focal
segmental sclerosis with interstitial fibrosis [21,32,33].
The etiology of renal involvement isn’t completely
understood, but can be related to poor metabolic control
[21], and the optimization of metabolic control can im-
prove renal disease [34]. Some studies [4,35,36] have
postulated a possible role of excessive renin-angiotensin
activity in the development of hyperfiltration and progres-
sive renal failure. When microalbuminuria is detected
angiotensin converting enzyme inhibitors should be
started without delay [37,38]. Proximal tubular dysfunc-
tion (Fanconi like syndrome) seems to be related to poor
metabolic control, being corrected after intensive dietary
treatment [1,8,21,31,33,39]. However, distal tubular
dysfunction may appear even in patients with optimal
metabolic control, and can lead to hypercalciuria and
hypocitraturia, which pose a risk to kidney stone for-
mation [40,41]; supplementation with citrate may be of
benefit in preventing or ameliorating urolithiasis and
nephrocalcinosis. Regular kidney ultrasound is re-
quired [1,8]. Hemodialysis and kidney transplantation
may be necessary once end-stage renal disease is
present [2,8]. In our case report, two out of five have
proteinuria without renal failure and not associated
with nephrocalcinosis. Our first case has proteinuria
since 6 years old, but angiotensin converting enzyme
inhibitor was only introduced when 17. Progressive
renal disease with nephrotic range proteinuria arose
and this patient is now under regular hemodialysis
program. Of notice is that one of the sibs of our 2nd
case has end-stage renal disease associated with focal
segmental glomerulosclerosis also under hemodialysis.
Besides the commonly reported manifestations and
complications, some conditions that might be associ-
ated with the disease are rarely recognized or reported.
One of them is depressive illness requiring therapy;
GSD type Ia poses an enormous burden for patients: a
lifelong intensive dietary therapy for 24 hours and the
fear for complications [1,8]. In our report, both female
patients had depressive illness needing anti-depressive
medication.
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with poor prognosis reported in some patients. The eti-
ology is unclear, but abnormalities in serotonin metabol-
ism have been proposed [2,4,42,43]. This complication
hasn’t been reported in neither of our patients till now.
Although irregular menstruation cycles and polycystic
ovaries are frequently described in GSD type Ia female
patients, fertility seems not to be impaired, since there
are reports of successful pregnancies [44,45]. However,
attention should be paid to the possibility of enlargement
of HCA during pregnancy, so close monitoring is neces-
sary [45]. Likewise, careful supervision in mandatory in
the third trimester, as the rapid fetal growth in this period
implies maintaining a state of euglycemia for achieving a
normal fetal outcome [44]. One of our patients had a nor-
mal pregnancy after liver transplantation and one of our
male patients has a healthy child.Conclusion
Since the first description of GSD I major progress has
been made in what concerns the knowledge of the clin-
ical, biochemical, genetic features and natural history of
the disease. This allowed advances in therapy, mainly
dietary therapy, with improvement of survival and qual-
ity of life. Hyperlipidemia, almost always present, should
be treated to reduce the risk of cholelithiasis and pan-
creatitis. Increased cardiovascular risk, although rarely
reported, is becoming a raising concern. In fact the fre-
quent association of GSD I and renal dysfunction results
in additional risk. Yet, the small number of patients in
each center makes it difficult to have randomized clinical
trials and the recommendations are based on clinical ex-
perience more than large scale studies.Consent
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